title: Novel therapies for advanced squamous cell carcinoma of the lung.
abstract: Advanced squamous non-small-cell lung carcinoma (SqCC) has traditionally been considered the 'neglected sibling' compared with lung adenocarcinoma due to lack of effective targeted treatment options. Currently, limited progress has been made in the systemic treatment of advanced disease and combination chemotherapy remains the gold standard. However, the recent completion of the molecular characterization of SqCC revealed an interestingly complex genomic profile, comprising various genetic alterations that can potentially function as molecular targets for the development of novel targeted agents. Recent encouraging results of the use of immune checkpoint inhibitors in several neoplasms has emerged as a promising novel treatment option for advanced SqCC. Future personalized studies, enrolling SqCC patients according to specific driving mutations are underway.
authors.affiliation: Medical Oncology Department, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Koutsoukos
authors.affiliation: Department of Medical Oncology, 251 Airforce General Hospital, 115 25, Athens, Greece.
authors.forename: Giannis
authors.initials: G
authors.lastname: Mountzios
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000209:etiology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000209:etiology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors
keywords: NSCLC; non-small-cell lung cancer; novel therapies; review; squamous